ALBIREO PHARMA INC's ticker is ALBO and the CUSIP is 01345P106. A total of 105 filers reported holding ALBIREO PHARMA INC in Q2 2022. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $16,705 | +735.2% | 773 | +854.3% | 0.00% | – |
| Q3 2022 | $2,000 | -66.7% | 81 | -71.2% | 0.00% | – |
| Q2 2022 | $6,000 | -25.0% | 281 | +3.3% | 0.00% | – |
| Q1 2022 | $8,000 | -85.7% | 272 | -88.7% | 0.00% | – |
| Q4 2021 | $56,000 | -79.6% | 2,411 | -72.6% | 0.00% | – |
| Q3 2021 | $274,000 | +5.0% | 8,796 | +18.7% | 0.00% | – |
| Q2 2021 | $261,000 | +33.2% | 7,409 | +33.1% | 0.00% | – |
| Q1 2021 | $196,000 | -63.2% | 5,566 | -60.8% | 0.00% | -100.0% |
| Q4 2020 | $533,000 | -58.1% | 14,217 | -62.7% | 0.00% | -75.0% |
| Q3 2020 | $1,273,000 | – | 38,148 | +1907300.0% | 0.00% | – |
| Q4 2018 | $0 | – | 2 | 0.0% | 0.00% | – |
| Q3 2018 | $0 | – | 2 | 0.0% | 0.00% | – |
| Q2 2018 | $0 | – | 2 | 0.0% | 0.00% | – |
| Q1 2018 | $0 | – | 2 | 0.0% | 0.00% | – |
| Q4 2017 | $0 | – | 2 | 0.0% | 0.00% | – |
| Q3 2017 | $0 | – | 2 | 0.0% | 0.00% | – |
| Q2 2017 | $0 | -100.0% | 2 | -99.7% | 0.00% | – |
| Q1 2017 | $14,000 | -36.4% | 602 | -52.1% | 0.00% | – |
| Q4 2016 | $22,000 | – | 1,257 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 514,082 | $11,973,000 | 7.17% |
| Privium Fund Management B.V. | 379,117 | $8,959,000 | 1.78% |
| Birchview Capital, LP | 113,000 | $2,632,000 | 1.70% |
| Sio Capital Management, LLC | 213,913 | $4,982,000 | 1.50% |
| Perceptive Advisors | 4,720,278 | $109,936,000 | 0.85% |
| Chicago Capital, LLC | 849,239 | $19,779,000 | 0.74% |
| APOGEM CAPITAL LLC | 38,601 | $899,000 | 0.59% |
| Samsara BioCapital, LLC | 100,000 | $2,329,000 | 0.45% |
| Artal Group S.A. | 600,000 | $13,974,000 | 0.38% |
| RICE HALL JAMES & ASSOCIATES, LLC | 458,011 | $10,667,000 | 0.38% |